PPDI reiterated at buy by Jefferies

Jefferies & Co., Inc. analyst David Windley reiterated Pharmaceutical Product Development, Inc. (PPDI) at a buy with a $44.50 price target. The company's reported net bookings beat the analyst's estimate by 12%, or $46 million, as it increases visibility to sustain 20%-plus revenue growth. According to the analyst, PPDI is also maintaining its leadership in phase 2-4 drug development. Total revenues were up 21% at $290 million. Shares of the Wilmington, N.C.-based pharmaceutical company were down $1.12, or 3.04%, at $35.68. (Nasdaq: PPDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.